Rho GDP dissociation inhibitor‑β in renal cell carcinoma

  • Authors:
    • Christoph‑Alexander von Klot
    • Natalia Dubrowinskaja
    • Inga Peters
    • Jörg Hennenlotter
    • Axel S. Merseburger
    • Arnulf Stenzl
    • Markus A. Kuczyk
    • Jürgen Serth
  • View Affiliations

  • Published online on: October 20, 2017     https://doi.org/10.3892/ol.2017.7233
  • Pages:8190-8196
Metrics: PDF 0 views | HTML 0 views
0

Abstract

Rho GDP dissociation inhibitor‑β (ARHGDIB) is an important mediator of cell signaling. The expression of ARHGDIB is associated with tumor growth and metastasis in a variety of non‑genitourinary cancers; however, the role of ARHGDIB in renal cell carcinoma (RCC) has not yet been evaluated. In the present study, tissue samples from 105 patients undergoing surgery for RCC were obtained. The expression levels of ARHGDIB mRNA in normal kidney tissues and in corresponding cancer tissues were analyzed by reverse transcription‑quantitative polymerase chain reaction. Differences in relative mRNA expression levels were assessed using paired two‑sample t‑tests. Expression levels were analyzed with respect to various clinical parameters, and associations were tested using a bivariate logistic regression model. Relative mRNA expression levels in healthy renal tissues compared with cancerous tissues from the same kidney were assessed using paired t‑tests. Expression data were compared with respect to survival data by the Kaplan‑Meier method/Cox regression analysis. The results revealed that the relative mRNA expression level of ARHGDIB was significantly higher in the lysates of RCC tumor tissues (P<0.001) when compared with healthy renal tissues in a paired analysis of 74 samples; this finding was consistent with the analysis of ARHGDIB mRNA expression levels in all RCC samples, as well as in the subset of clear cell RCC (ccRCC) samples. The relative mRNA expression level of ARHGDIB was also increased in ccRCC tissues compared with papillary RCC tissues (P<0.001). On univariate Cox regression analysis, recurrence‑free survival (RFS) was significantly associated with metastasis, locally advanced disease and tumor grade (P=0.018, P=0.002 and P<0.001, respectively). Furthermore, in the subgroup of patients with ccRCC, increased ARHGDIB mRNA expression was significantly associated with a longer RFS time (P=0.001). In summary, the results indicate that ARHGDIB mRNA is highly expressed in RCC tissues in general and is positively associated with RFS in ccRCC. As ARHGDIB has a known effect on angiogenesis and immune modulation, the present study suggests that the functional analysis of ARHGDIB should be performed in the future.

Related Articles

Journal Cover

December 2017
Volume 14 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

2016 Impact Factor: 1.39
Ranked #68/217 Oncology
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
von Klot, C., Dubrowinskaja, N., Peters, I., Hennenlotter, J., Merseburger, A.S., Stenzl, A. ... Serth, J. (2017). Rho GDP dissociation inhibitor‑β in renal cell carcinoma. Oncology Letters, 14, 8190-8196. https://doi.org/10.3892/ol.2017.7233
MLA
von Klot, C., Dubrowinskaja, N., Peters, I., Hennenlotter, J., Merseburger, A. S., Stenzl, A., Kuczyk, M. A., Serth, J."Rho GDP dissociation inhibitor‑β in renal cell carcinoma". Oncology Letters 14.6 (2017): 8190-8196.
Chicago
von Klot, C., Dubrowinskaja, N., Peters, I., Hennenlotter, J., Merseburger, A. S., Stenzl, A., Kuczyk, M. A., Serth, J."Rho GDP dissociation inhibitor‑β in renal cell carcinoma". Oncology Letters 14, no. 6 (2017): 8190-8196. https://doi.org/10.3892/ol.2017.7233